Novartis, shadowed by data scandal, renews case for Zolgensma

Novartis, shadowed by data scandal, renews case for Zolgensma

Source: 
Biopharma Dive
snippet: 

Infants likely to develop a severe form of spinal muscular atrophy, but who were not yet symptomatic, could sit and stand following treatment with Novartis' gene therapy Zolgensma, according to new study results disclosed by the Swiss drugmaker.